Stockwinners Market Radar for June 03, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:34 EDT Pilgrim's Pride comments on DOJ indictment against current executive - The company states: "Pilgrim's was informed of an indictment against a current executive and two former Pilgrim's employees. We take this matter very seriously. The company is committed to high ethical standards, governance, and free and open competition that benefits both customers and consumers. Pilgrim's will continue to fully cooperate with the Department of Justice in their investigation."

18:56 EDT Universal Health Realty ups quarterly dividend by 0.5c per share to 69c - Universal Health Realty Income Trust announced that its Board of Trustees voted to increase the quarterly dividend by 0.5c and pay a dividend of 69c per share on June 30, 2020 to shareholders of record as of June 16, 2020.

18:53 EDT AcelRx says will not further revise offer to acquire Tetraphase - AcelRx (ACRX) announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals (TTPH), and it expects the agreement to be terminated by Tetraphase. On June 1, Tetraphase disclosed that its board of directors had determined that an amended proposal from Melinta Therapeutics constituted a "Superior Offer" under the terms of the AcelRx Merger Agreement. Under the terms of the agreement, in connection with a termination of the merger agreement, AcelRx will be paid a break-up fee of approximately $1.8M. Vince Angotti, CEO at AcelRx said, "AcelRx is financially disciplined, and while we continue to recognize the merits of an AcelRx and Tetraphase combination, we do not believe that any further increases to our offer would be in the best interests of our stockholders. As a result, we have decided not to further increase our offer and will focus on other exciting opportunities to expand and diversify our product portfolio and create a platform for growth with other potential collaboration partners." The co-promotion agreement between AcelRx and Tetraphase remains in place, safeguarded by significant financial obligations. The training of both the AcelRx and Tetraphase teams is complete and co-promotion efforts for DSUVIA and XERAVA are currently underway.

18:37 EDT Crowdstrike CEO: Cyber crime up 'big time' due to COVID-19 - In an interview on CNBC's Mad Money, George Kurtz said cyber crime often happens when folks are not at work. According to Kurtz, Crowdstrike stopped 35,000 in-process breaches last year. Part of the company's solution is using AI to prevent never seen before attacks from occurring, he said. "The more data we consume, the smarter we get, the better we protect." Going forward, Kurtz sees the workplace becoming a hybrid model of home/office where "work from anywhere" is encouraged.

17:48 EDT Facebook's Overwsight board not yet reviewing posts from public figures - Facebook's Oversight Board said in a blog post that it is not fully operational yet and that it is on the pathway towards the board hearing its first case over the coming months. "The Oversight Board was created to make binding and independent decisions on the most challenging content issues on Facebook and Instagram," the board said. "As such, how Facebook treats posts from public figures that may violate their community standards are within the scope of the Board, and are the type of highly challenging cases that the Board expects to consider when we begin operating in the coming months." "As an institution that announced our first members less than a month ago, and which will not be operational until later this year, we are not in an immediate position to make decisions on issues like those we see unfolding today," the board continued. "As a deliberative body, we also do not expect to regularly weigh in on issuing opinions about global events - our focus is on making decisions about content that is on Facebook and Instagram. We are working hard to build a strong institution that is designed to operate and deliver results over the long term. For a Board that will consider deeply challenging questions, and that will serve a global community, we want to move as quickly as possible while also recognising the care with which this institution must be crafted." The Fly notes that the blog post comes after Facebook employees this week protested the company's decision to not to take down a post from U.S. President Donald Trump, where the president addressed riots in the aftermath of George Floyd's death, saying that "when the looting starts, the shooting starts." Reference Link

17:25 EDT Expeditors CFO Bradley Powell sells over $1.4M in company shares - Expeditors CFO Bradley Powell disclosed in a filing that he had sold 18,470 shares of company stock at $76.75 per share on June 2. The total transaction value of the sale was $1,417,536.

17:07 EDT Regional Management sees 'positive credit trends' continue into May - In its Business Update press release, the company states: "Positive credit trends continued into May, with our 30+ day contractual delinquency rate decreasing to 5.0% as of May 31, 2020, an improvement of 40 basis points from April 30, 2020, 160 basis points from March 31, 2020, and 120 basis points from May 31, 2019. As of May 31, 2020, 30+ day contractual delinquency totaled $51.5M, compared to $57.3M as of April 30, 2020, $72.4M as of March 31, 2020, and $60.2M as of May 31, 2019. We expect that our 30+ day contractual delinquency rate will be below 6.0% as of June 30, 2020, and will increase throughout the balance of the year due to the impact of COVID-19 and normal seasonality. Given the recent low delinquency levels, we expect COVID-19 related credit losses to be pushed back to Q4 of 2020 and into 2021. The overall level of losses will depend on, among other things, the pace at which state economies rebound, the unemployment rate, and whether federal and state governments enact further stimulus measures."

17:01 EDT Amplify Energy regains compliance with NYSE minimum price listing standard - Amplify Energy Corp. announced that on June 2, 2020, Amplify was notified by the New York Stock Exchange that the company has regained compliance with the NYSE's continued listing standards. On April 20, 2020, Amplify received notification from the NYSE that the company had fallen below the continued listing standard to maintain a minimum average closing price of $1.00 per share over 30 consecutive trading days. Amplify regained compliance after its average closing price for the 30 trading days ended May 29, 2020 and its closing price on May 29, 2020 both exceeded $1.00 per share. The below compliance indicator has been removed from the company's common shares, and the company was removed from the NYSE list of non-compliance issuers.

16:46 EDT Riot Blockchain purchases additional 1,000 Bitmain S19 Pro Antminers - Riot Blockchain, Inc. has purchased an additional 1,000 next-generation Bitmain S19 Pro Antminers for USD $2.3 million from BitmainTech PTE. This purchase was funded using available working capital and Riot has no long-term debt. By Q4 2020, without any further miner purchases, Riot estimates its aggregate operating hash rate to be approximately 567 petahash per second consuming 14.2 megawatts of power, assuming full deployment of the total 7,040 next-generation miners. This would represent an estimated 467% over Riot's average mining hash rate as of late 2019 and an efficiency rating of 38.6 joules per terahash versus 98 J/TH in 2019. These new generation miners are expected to operate at nearly 467% of the late 2019 hash rate, utilizing only approximately a 50% increase in energy consumption. Riot anticipates that the additional S19 Pro & S19 3,040 miners will be deployed as received in the second half of 2020 and are estimated to represent over 56% of Riot's total hashing capacity. These miners will be deployed at Coinmint's Massena facility pursuant to the previously disclosed hosting arrangement that Riot entered as part of its continuing efforts to significantly decrease costs of production. The May 2020 halving, the third in the network's history, means the mining reward has now been reduced from 12.5 bitcoins per block to 6.25 block rewards. Bitcoin miners continue to face pressure from the halving event which occurred in May 2020, as the event directly affected mining revenues. Mine operators that failed to upgrade to more efficient mining rigs and / or secure cheaper power may succumb to the negative effects of the halving event. In 2020, Riot reinforced its confidence in bitcoin by focusing on bitcoin mining and further investing in a full upgrade & expansion of its mining fleet with the objective of increasing operational efficiency and performance in the post-halving mining environment.

16:44 EDT Qorvo VP James Klein sells over $520K in company shares - Qorvo VP James Klein disclosed that he had sold 5,000 shares of company stock at $104.74 per share on June 1. The total transaction value of the sale was $523,700.

16:28 EDT Luby's to pursue sale of operations and assets - Luby's announced it will immediately pursue the sale of its operating divisions and assets, including its real estate assets, and distribute the net proceeds to stockholders after payment of debt and other obligations. Luby's will "explore a variety of potential transactions, including selling the company's operating divisions: Luby's Cafeteria, Fuddruckers, and Culinary Contract Services, as well as its real estate, or selling the company in its entirety," the company stated. Net proceeds obtained from these transactions, after satisfying the company's debt and other obligations, will ultimately be distributed to Luby's stockholders, the company stated in its press release regarding the sale.

16:22 EDT Inovio files complaint against VGXI related to COVID-19 vaccine supply - In a regulatory filing, Inovio Pharmaceuticals disclosed that it has filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania seeking, among other requests for emergency relief, to compel VGXI, Inc. and GeneOne Life Science to facilitate the transfer of manufacturing methods, using VGXI's technology, under the parties' existing supply agreement. The technology transfer, which the company has requested as permitted under the supply agreement, will allow for the large-scale manufacture of the company's product candidate INO-4800, a new vaccine candidate against the disease, known as COVID-19, caused by the outbreak strain of the coronavirus SARS-CoV-2. The company believes that widespread availability of its potential COVID-19 vaccine, which can only be achieved through accelerated large-scale manufacture following clinical trials and regulatory approval, is essential to combat the ongoing global coronavirus pandemic. The filing added: "VGXI informed the company that it did not have the capacity to manufacture the company's full order of DNA plasmids on the requested timeline, nor would it be able to manufacture plasmids for the commercial sale of INO-4800, if it were to be approved for sale. The company began discussions with other third-party contract manufacturers, as permitted by the supply agreement. As previously announced, in March and April 2020, the Company engaged Ology Bioservices Inc. and Richter-Helm BioLogics GmbH & Co. KG to support large-scale manufacturing of INO-4800...The company intends to engage additional contract manufacturers for the production of INO-4800. Following notification of VGXI's insufficient capacity, the company requested that VGXI provide the necessary technology transfer materials in order to allow its engaged contract manufacturers to proceed with the manufacture of INO-4800, as required by the supply agreement. In May 2020, following further discussions between the parties, VGXI notified the company of its refusal to undertake the company's request, leading the company to initiate legal proceedings as an emergency action to compel the technology transfer required of VGXI by the supply agreement for the planned large-scale manufacture of the company's COVID-19 vaccine candidate."

16:17 EDT Mitcham Industries seeking shareholder approval for Delaware reincorporation - Mitcham Industries is seeking shareholder approval for a reincorporation from the State of Texas to Delaware, which will include rebranding and renaming the company MIND Technology. CEO Rob Capps stated, "After making significant progress over the past year transforming Mitcham away from its traditional oil and gas activities, we strongly believe our rebranding effort better reflects our technological advantages and core competencies, and will enhance our sales and marketing efforts to our target markets and end customers. In connection with these proposed changes and in recognition of our focus on our marine technology products business, as well as recent changes in the global energy markets, we think that it's now appropriate to further de-emphasize our land seismic leasing business. Accordingly, we have decided to make no new investments in land seismic lease pool equipment and will attempt to maximize the value of our existing operations and equipment through leasing or sales transactions. We are also taking steps to adjust the cost structure of this portion of our business to reflect the ongoing operations".

16:15 EDT Smartsheet falls over 20% to $47.33 per share after Q1 results and guidance - Shares of Smartsheet are down 20% at $47.33 after its Q1 results and below-consensus guidance for Q2. The company also cut its FY21 revenue outlook to $360M-$370M from $373M-$378M guided in March.

16:14 EDT Harte-Hanks selected by Flagship Biosciences to provide marketing solutions - Harte Hanks announced that it has been selected by Flagship Biosciences to provide strategic marketing solutions in developing a new customer acquisition program. Harte Hanks will be developing a targeted, multi-channel campaign including email, digital advertising and content creation to help Flagship Biosciences engage priority audiences, nurture leads and connect with potential clients.

16:13 EDT Cloudera down over 6% to $11.63 after Q2, FY21 revenue view misses estimates

16:12 EDT Air Transport jumps 11% to $23.50 after Amazon leases 12 additonal planes

16:11 EDT Cloudera sees FY21 subscription revenue $745M-$755M

16:10 EDT Cloudera CEO says 'We executed extremely well in Q1' - "We executed extremely well in Q1, particularly as the pandemic was in full effect for more than half of our fiscal quarter," said Rob Bearden, CEO, Cloudera. "We believe that remote working environments have placed heightened importance on data, data analysis and data security, which has increased the value of data architecture design and the criticality of hybrid cloud solutions. In addition, CDP Public Cloud is accomplishing exactly what we had hoped in that it has enabled a hybrid multi-cloud architecture for our customers and enhanced our value proposition with customers who plan to take advantage of public cloud infrastructure for certain types of workloads."

16:07 EDT Fitbit unveils Fitbit Flow ventilator for use during COVID-19 public emergency - Fitbit announced it has developed a "high-quality, low-cost, easy-to-use emergency ventilator", Fitbit Flow, which has obtained Emergency Use Authorization from the FDA for use during the COVID-19 public health emergency. Fitbit is in talks with state and federal agencies to understand current domestic needs for emergency ventilators and plans to work with U.S. and global aid organizations as well, both today and ahead of any future waves of the virus.

16:05 EDT NetApp to acquire Spot, terms not stated - NetApp announced it has entered into a definitive agreement to acquire Spot, a "leader in compute management and cost optimization on the public clouds, to establish leadership in Application Driven Infrastructure." Spot provides a combination of tools for visibility and automation, that drive continuous optimization of workloads in a single platform while maintaining both SLA and SLO. Together, "NetApp and Spot will establish an Application Driven Infrastructure to enable customers to deploy more applications to public clouds faster with Spot's "as-a-service" platform for the continuous optimization of both compute and storage for both traditional IT buyers with enterprise applications, cloud-native workloads and data lakes." The transaction is expected to close in the first half of NetApp's fiscal year and is subject to the satisfaction of certain regulatory approvals and other customary closing conditions.

16:02 EDT Amazon.com expands air fleet with 12 converted Boeing 767-300 aircraft - Amazon (AMZN) continues to adapt to meet the changing needs of customers by investing in ways to provide fast, free delivery. Today, the company announced the lease of 12 Boeing (BA) 767-300 converted cargo aircraft from Air Transport Services Group (ATSG). These aircraft will join Amazon's existing fleet of 70 aircraft to bring its total network to over 80 aircraft. One of the new aircraft joined Amazon's air cargo operations in May 2020, with the remaining 11 to be delivered in 2021.

15:30 EDT Hyatt extends change and cancellation policy for stays through July 31, 2021 - Hyatt Hotels announced an extension to its cancellation policy that will "provide further flexibility as guests start making travel decisions again." The company said: "With some limited exceptions, reservations booked July 1, 2020 and beyond - for any future arrival date through July 31, 2021 - can be cancelled at no charge up to 24 hours before scheduled arrival. This includes Advance Purchase Rate reservations." Reference Link

15:14 EDT Trump administration bans Chinese passenger carriers from U.S. flights - The Trump administration has banned Chinese passenger carriers from flying to the U.S. starting in mid-June. The Department of Transportation said the order will be served on Air China (AIRYY), Beijing Capital Airlines, China Eastern Airlines (CEA), China Southern Airlines (ZNH), Hainan Airlines, Sichuan Airlines, and Xiamen Airlines. CHINESE PASSENGER CARRIER BAN: According to the Department of Transportation, "responding to the failure of the Government of the People's Republic of China to permit U.S. carriers to exercise the full extent of their bilateral right to conduct scheduled passenger air services to and from China, we will serve this Order on Air China Limited d/b/a/ Air China; Beijing Capital Airlines Co., Ltd.; China Eastern Airlines Corporation Limited; China Southern Airlines Company Limited; Hainan Airlines Holding Co. Ltd.; Sichuan Airlines Co., Ltd.; and Xiamen Airlines; all certificated U.S. carriers operating large aircraft; the Embassy of the People's Republic of China in Washington, D.C.; the Civil Aviation Authority of China; the Department of State; the Transportation Security Administration; and the Federal Aviation Administration." Publicly traded U.S. air carriers that have offered passenger flights to China include American Airlines (AAL), Delta (DAL) and United (UAL). PRICE ACTION: In afternoon trading in New York, shares of Air China have dropped almost 1% to $12.90. Meanwhile, China Eastern Airlines is fractionally up at $18.58 and China Southern Airlines has gained over 2% to $22.58. Reference Link

14:50 EDT PDL Community Bancorp approved by NYDFS to acquire Mortgage World Bankers - PDL Community Bancorp, the holding company for Ponce Bank, reported that the New York State Department of Financial Services has approved the company's acquisition of 100% of the stock of Mortgage World Bankers, a mortgage banking company headquartered in Astoria, New York. Michael Lagoudis will continue to manage MWB's operations as its President and CEO and will become a Senior Vice President of the company. The acquisition is expected to close on or about July 1. Carlos Naudon, President and CEO of the company, noted that "this purchase will enhance our mortgage origination capacity, enable us to offer more competitive consumer mortgage products in our communities, give us an experienced and established channel to the secondary markets and expand our reach into additional communities. Further, we expect the transaction will be accretive well within 18 months."

14:23 EDT Bohemia CEO says Tencent investment report 'not true' - According to a post in Bohemia Interactive's forum, Bohemia CEO Marek Spanel said that reports of Tencent acquiring a stake in the company are "not true." "We were talking to numerous potential partners in the past about possible strategic cooperation and we may do so in the future as well but as of now, we remain an independent studio," he said. Reference Link

13:54 EDT Advertising tech stocks spike higher after Criteo says revenue trends better - Shares of companies who have businesses relate to the advertising technology space are higher after one of their peers, Criteo (CRTO), made encouraging statements on Wednesday. CRITEO COMMENTARY: The advertising tech company on Wednesday provided an interim update on its second quarter financial performance, saying that "a continued decline of the company's revenues for the month of May compared to April had not materialized as anticipated." As of May 29, Criteo said overall revenue trends have been better than were expected at the time of the company's April 29 guidance for the second quarter of 2020. Additionally, the company believes it is on track to achieve its cost savings targets as anticipated in its April 29 guidance for the second quarter. ANALYST HAD LOWERED TARGETS: In early May, both Deutsche Bank and SunTrust lowered their price targets on Criteo. Deutsche Bank analyst Lloyd Walmsley lowered the firm's price target on Criteo to $16 from $22 on May 8 and kept a Buy rating on the shares. SunTrust analyst Matthew Thornton lowered the firm's price target on Criteo to $13 from $25 and also kept a Buy rating on the shares. Thornton said in a research note at the time that he sees Q1 results as "solid" given the COVID-19 outbreak and the FX headwinds, while adjusting his model to 10-times expected free cash flows and for enterprise value at 0.2-times expected gross sales. Thornton remained positive on Criteo's "very reasonable consensus and expected continued cash generation." PRICE ACTION: Shares of Criteo are up nearly 17% to $13.00 in afternoon trading. PEERS TRADE HIGHER: Advertising technology peers are higher, including Rubicon Project (RUBI), Cardlytics (CDLX), QuinStreet (QNST), Trade Desk (TTD) and TechTarget (TTGT).

13:18 EDT Inovio drops 7% to $13.32 after White House omits as vaccine finalist

13:17 EDT General Motors CEO sees close to normal capacity in Mexico in June - Comments taken from Wolfe Research conference.

13:00 EDT Pilgrim's Pride CEO among four indicted by DOJ for chicken price fixing - A federal grand jury in the U.S. District Court in Denver, Colorado, returned an indictment against four executives for their role in a conspiracy to fix prices and rig bids for broiler chickens, the Department of Justice announced in a statement. The one-count indictment charges four current and former senior executives from two major broiler chicken producers with conspiring to fix prices and rig bids for broiler chickens. Broiler chickens are chickens raised for human consumption and sold to grocers and restaurants. According to the indictment, from at least as early as 2012 until at least early 2017, Jayson Penn, Roger Austin, Mikell Fries, and Scott Brady conspired to fix prices and rig bids for broiler chickens across the United States. Penn is the President and Chief Executive Officer, and Austin is a former Vice President, of Pilgrim's Pride (PPC). Fries is the President and a member of the board, and Brady is a Vice President, of Claxton Poultry Farms. Following the announcement, shares of Pilgrim's Pride are down 13%, or $2.74, to $18.13. Meat producer peers Sanderson Farms (SAFM) and Tyson Foods (TSN) are traded lower following news of the indictment.

12:57 EDT Third Point confirms owning Boeing debt, not equity - Contacted by The Fly, a spokesperson for Third Point confirmed that its new position in Boeing is credit, not equity. Dan Loeb's Third Point Offshore Fund listed Boeing as one of its monthly winners for May, along with Disney (DIS), Burlington Stores (BURL), Charter Communications (CHTR) and TE Connectivity (TEL).

12:51 EDT Pilgrim's Pride sinks 13% to $18.09 after CEO indictment on price fixing - Shares of Sanderson Farms (SAFM) are down 9% to $118.74 while Tyson Foods (TSN) is down 3% to $60.64.

12:36 EDT Pilgrims Pride trading halted, volatility trading pause

12:17 EDT Tiffany down 1% after Reuters says LVMH looking for way to renegotiate deal - A report from Reuters' Greg Roumeliotis and Pamela Barbaglia said that LVMH (LVMUY) CEO Bernard Arnault is looking at ways to reopen negotiations on the proposed acquisition of Tiffany (TIF) for $16.2B, echoing a similar report yesterday from Women's Wear Daily. Arnault has been in talks with his advisers to find ways to pressure Tiffany to lower the agreed upon deal price of $135 per share and is considering if LVMH can successfully argue that Tiffany is in breach of its deal obligations, Reuters said. In early afternoon trading, Tiffany shares are down about 1% to $115.48. Reference Link

12:00 EDT Direxion Financial Bear 3x falls -9.4% - Direxion Financial Bear 3x is down -9.4%, or -$1.73 to $16.66.

12:00 EDT China Online Education falls -13.1% - China Online Education is down -13.1%, or -$3.04 to $20.25.

12:00 EDT At Home Group rises 23.4% - At Home Group is up 23.4%, or $1.18 to $6.23.

11:54 EDT Paradox to sign collective bargaining agreement with Unionen, SACO unions - Paradox Interactive announced the impending completion of a collective agreement between the company and its employees' labor unions, Unionen and SACO. Under the terms of the agreement, Paradox employees have a formalized means of influencing their pay, benefits, responsibilities, and more. The agreement will apply to all Paradox employees working at locations within Sweden as of its implementation, expected to be finalized within the quarter. "In the 20-plus years we've been in operation, Paradox has always been a growing company, but that growth has been especially dramatic in the last few years," said Marina Hedman, Chief Human Resources Officer at Paradox Interactive. "An organization of our size has different needs, and we must ensure that our employees continue to feel valued and empowered to shape our company, even as our structure shifts towards larger teams and projects. We're proud, both as a Swedish company and as a member of the games industry, to add our name to the roster of companies who support unionization." The agreement helps enshrine a number of current Paradox company standards, ensuring that employee benefits, paths to career growth, and salary expectations continue to meet everybody's needs. The agreement will apply to Paradox's studios located within Sweden, including Paradox Interactive, Paradox Development Studio, Paradox Arctic, and Paradox Malmo.

11:44 EDT Google Cloud and the UK government sign MoU to boost cloud innovation - Google Cloud announced that it has signed a Memorandum of Understanding, MoU, with UK Crown Commercial Service, CCS. "The intent of the MoU is to make it easier and more affordable for UK public sector agencies to leverage the full range of Google Cloud's services to increase innovation and deliver digital transformation. CCS, the UK Cabinet Office executive agency and trading fund, engaged Google Cloud in 2019 to discuss requirements for cloud services under the One Government Cloud Strategy, a joint initiative between Cabinet Office, CCS and Government Digital Service. CCS aims to open up the cloud services market to more suppliers to provide the best value and terms for public sector agencies investing in cloud technology. Working collaboratively with CCS, Google Cloud has confirmed a discount for qualifying public sector bodies based on aggregated cloud service demand and expected spend. Together, CCS and Google Cloud are breaking down the barriers to cloud adoption for all eligible UK public sector organizations, such as government departments, local councils, arm's length bodies, NHS bodies, public funded broadcasters, and charities. This will allow organizations to take full advantage of a range of technologies across Google Cloud, including infrastructure, analytics, artificial intelligence, application modernization and development, and collaboration solutions," said Google in a statement. Reference Link

11:39 EDT Translate Bio holder Shire Human Genetic Therapies sells over $4M in shares - Translate Bio holder Shire Human Genetic Therapies disclosed that it sold 213,867 shares of company stock at $19.81 per share between June 1 and June 2 for a total transaction value of $4,237,026.

11:33 EDT Nikola and VectoIQ close deal, to trade under new symbol 'NKLA' on June 4 - Nikola Corporation announced the completion of its previously announced business combination with VectoIQ Acquisition Corp. (VTIQ), a publicly-traded special purpose acquisition company, and Nikola's listing on the Nasdaq Global Select Market. The business combination, which was approved on June 2 by VectoIQ stockholders, "further solidifies Nikola as a global leader in zero-emissions transportation and infrastructure solutions," the company said. On June 4, the combined company's shares will trade on the Nasdaq under the new ticker symbol "NKLA." "The transaction proceeds are expected to accelerate vehicle production, allow Nikola to break ground on its state-of-the-art manufacturing facility in Coolidge, Arizona, and continue its hydrogen station infrastructure roll out," the company added.

10:56 EDT Moderna CEO says no COVID vaccine manufacturer can supply planet - Moderna CEO Stephane Bancel, while speaking at a Jefferies conference, said no company of a potential COVID-19 vaccine will have enough to supply the entire planet. As such, Bancel hopes multiple vaccines "cross the finish line."

10:46 EDT Moderna CEO says 8 patient COVID data released due to lack of control - Moderna CEO Stephane Bancel said during a Jefferies conference presentation that his company decided to release the eight patient COVID-19 vaccine study early due to a lack of control over the data. Bancel said the board determined the company could not ensure the material information wouldn't be disclosed by others since people outside the company had the data, including those at the National Institutes of Health.

10:00 EDT Retailwinds trading resumes

09:47 EDT China Online Education falls -6.4% - China Online Education is down -6.4%, or -$1.48 to $21.81.

09:47 EDT VelocityShares 3x Inv Natural Gas ETN falls -12.7% - VelocityShares 3x Inv Natural Gas ETN is down -12.7%, or -$39.95 to $274.62.

09:47 EDT American Eagle rises 13.7% - American Eagle is up 13.7%, or $1.41 to $11.70.

09:39 EDT Newater says Independent Committee engages financial advisor, legal counsel - Newater Technology announced that the special committee of its board of the directors, which consists of independent directors and was formed to consider, among other things, the May 12, 2020 non-binding proposal letter from the Company's chairman and CEO Yuebiao Li and its CFO Zhuo Zhang, to acquire all of the outstanding shares of the Company not currently owned by the Buyer Group and their respective affiliates and certain other shareholders of the Company who may choose to join the Buyer Group in a going private transaction, has retained Duff & Phelps, LLC as its financial advisor and MagStone Law, LLP as its legal counsel to assist the Independent Committee in its work. No decisions have been made by the Independent Committee with respect to the Company's response to the proposed transaction. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The Independent Committee is continuing its evaluation of the Proposed Transaction. The Company does not undertake any obligation to provide any updates with respect to the Proposed Transaction or any other transaction, except as required under applicable law.

09:35 EDT PAVmed collaborates with Canon on DisappEAR pediatric ear tubes - PAVmed (PAVM) announced the company and Canon (CAJ) United States manufacturing and technology center, Canon Virginia,, have executed a letter of intent to consummate a series of agreements to develop and utilize Canon Virginia's commercial grade and scalable aqueous silk fibroin molding process to manufacture PAVmed's DisappEAR molded pediatric ear tubes for commercialization. Under terms outlined in the LOI, PAVmed and Canon Virginia propose to enter into two sequential agreements covering a five-phase project culminating in the commercialization of PAVmed's DisappEAR molded pediatric ear tubes. PAVmed licensed the technology underlying its DisappEAR resorbable ear tube from Tufts University on behalf of itself and other leading academic institutions including, two Harvard Medical School teaching hospitals - Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital - as well as, Massachusetts Institute of Technology and Eidgenossisches Technishe Hochschule Zurich. The tubes are manufactured from a proprietary aqueous silk technology which is designed to slowly be reabsorbed over the intended course of treatment.

09:26 EDT OneSpaWorld holder DFAM comments on criticism by proxy firms of financing deal - Deep Field Asset Management, or DFAM, an adviser of funds that beneficially own 1.82M shares of OneSpaWorld Holdings Limited, issued a letter to OSW shareholders commenting on voting recommendations from proxy advisory firms Glass Lewis and Institutional Shareholder Services, or ISS, related to OSW's proposed $75 million financing. DFAM said in part in an open letter to shareholders, "DFAM thanks Glass Lewis and ISS for their careful attention to the arguments we have detailed over the past month. We believe that when taken together, the reports should convince any reasonable investor of the pressing need to vote AGAINST the contested proposals...We are confident that a majority of OSW's owners, with the interests of all shareholders in mind, will be 'reasonable' enough to vote AGAINST this awful proposal."

09:23 EDT OneSpaWorld holder DFAM comments on criticism by proxy firms of financing deal - Deep Field Asset Management, or DFAM, an adviser of funds that beneficially own 1.82M shares of OneSpaWorld Holdings Limited, issued a letter to OSW shareholders commenting on voting recommendations from leading proxy advisory firms Glass Lewis and Institutional Shareholder Services, or ISS, related to OSW's proposed $75 million financing. DFAM said in an open letter to shareholders, "DFAM thanks Glass Lewis and ISS for their careful attention to the arguments we have detailed over the past month. We believe that when taken together, the reports should convince any reasonable investor of the pressing need to vote AGAINST the contested proposals. Glass Lewis concluded that "conflicts of interest, apparent self-dealing and unfavorable terms of the transaction, together with what we consider relatively weak evidence of any mitigating factors or meaningful safeguards,"1 offer sufficient reason for OSW shareholders to oppose this deal. Glass Lewis adds that "OSW shareholders would be wise to base their voting decisions on all information available today," noting that the broad economic recovery over the course of the last few weeks has made a bad deal even worse for shareholders. Glass Lewis is crystal clear in its evaluation of this transaction as a harmful one for OSW shareholders. We agree wholeheartedly. While Describing OSW Shareholders as "Injured," ISS Only "Cautiously" Recommends a Vote For Proposals 3 and 4: While we regret that ISS chose to "cautiously" recommend a vote in favor of the transaction, we are heartened that its analysis in many ways affirms our position: the transaction OSW has submitted to its shareholders is a travesty of governance and a master course in self-dealing. As detailed throughout its report, ISS itself appears amazed at the repeated failure of OSW's management, Board of Directors, and Special Committee members to act in the best interests of all shareholders: "The dissident has raised valid concerns regarding potential self-dealing on the part of the participating special committee members." "There appears to be validity to the dissident's argument that the members of the special committee favored a private transaction, from which they will directly profit, over a public rights offering that would not offer the same personal benefit." "Given the degree of management's concern about the company's ability to continue as a going concern, it seems inexplicable that OSW did not start the process to submit a shelf registration to the SEC at the same time, even if just to preserve the option of a rights offering at a later date." "In plain terms, the fact that more than one of the potential counterparties offered the special committee members a personal incentive is no excuse. Whether such incentives are offered or demanded, the injured party is no less injured. Deep Field expresses this sentiment best when it says that, '[a] Special Committee prepared to accept unfair and conflicted terms is not any less offensive to good governance than one determined to propose them.'" These "concerns are magnified by the board and management's decision not to take even a symbolic pay reduction - as many other companies have - while furloughing a substantial portion of its employee base." In summary, ISS says that it is valid to describe members of OSW Leadership on the Special Committee as engaging in "self-dealing," "from which they will directly profit." ISS describes OSW Leadership's failure to have already taken steps to set the Company up for a possible alternative to their self-dealing transaction as "inexplicable," and says that the conflicts which led to this unfair deal have "no excuse." Indeed, ISS implies in no uncertain terms that OSW shareholders have been "injured" by OSW Leadership's bad behavior, including its callous decision to profiteer from COVID-19 rather than even taking a pay cut in solidarity with its furloughed employees. Because of these concerns, ISS notes that it could only "cautiously" recommend a vote in favor of the deal. ISS appears to have been persuaded primarily by OSW Leadership's argument that "there is a risk that other financing alternatives may not be readily available at this point." But ISS has also stated that we are "at this point" in large part thanks to the failures by OSW Leadership. They have placed our Company on the brink, and now imperiously demand we vote insiders an almost nine-figure windfall profit as ransom to save it. ISS does little in their report to hide their serious concerns surrounding this deal on fairness, governance and procedural grounds. While ISS ultimately "cautiously" recommended the deal, it was primarily because they were unsure of the risk around financing alternatives. Respectfully, we note that ISS are not experts in capital raising, and point out that their core reason to vote for the deal fails if the reader reasonably believes financing alternatives are available. We believe there are many alternatives available. The capital markets are wide open at the moment. OSW makes dire proclamations about the risk of going to market for financing, but dozens of deals are getting done at very moderate discounts (unlike the current proposal, which is at an almost 50% discount to today's share price). OSW Leadership's fear mongering is simply not grounded in reality. For example, just two nights ago Lindblad Expeditions filed a shelf registration indicating potential preparations for raising capital - and saw its shares climb more than 10% in response. Accordingly, we believe investors should read closely the portions of ISS's report that draw on its governance expertise (in which ISS excoriates OSW Leadership for their behavior throughout this process), pay less heed to its views on the availability of financing alternatives (investors can evaluate that question for themselves in light of the evidence in the market almost every day), and reasonably conclude that ISS's report offers a compelling argument for voting AGAINST the transaction. We note that ISS says "certain shareholders may reasonably choose to follow Deep Field's lead and vote against this transaction." For investors who see the wide availability of financing alternatives in today's market, ISS's report may read as highly supportive of our position that shareholders must vote AGAINST this transaction. To anyone with lingering doubts that OSW can quickly raise capital, we encourage you to call your favorite investment bank and simply ask the question. From the beginning of this process, DFAM has said that OSW does indeed need to raise capital, but that this transaction was the wrong one for myriad reasons - especially with capital markets wide open. This week, our position has been affirmed by both leading proxy advisors. Glass Lewis straightforwardly agrees with us in its official recommendation. On the other hand, ISS states that shareholders may "reasonably" choose to follow our recommendation, and it seems that would especially hold for investors who disagree with ISS's primary concern which is "the risk that other financing alternatives may not be readily available." It stands to reason that ISS sees clear merit in a shareholder who rejects this concern to vote AGAINST the transaction. DFAM believes it has unanimous support from the leading proxy advisors that, if an investor believes capital markets are open to OSW, a vote AGAINST this deal is justified. We have received inbound calls from many shareholders, all of whom have expressed the belief this deal is bad for the Company. It is offensive in the short-term because this deal was the result of an ugly process which has the effect of unduly enriching insiders and badly diluting unaffiliated shareholders. And it is also value-destructive in the long-term, because in a world where "ESG" investing is on the ascendancy, the specter of poor governance and utter contempt for unaffiliated shareholders will hang over the Company, its management, and members of its Board of Directors, for a long time to come. We are confident that a majority of OSW's owners, with the interests of all shareholders in mind, will be "reasonable" enough to vote AGAINST this awful proposal."

09:21 EDT Diana Shipping announces time charter contract for m/v G.P. Zafirakis - Diana Shipping has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for one of its Capesize dry bulk vessels, the m/v G. P. Zafirakis. The gross charter rate is $13,200 per day, minus a 5% commission paid to third parties, for a period until minimum October 1, 2021 up to maximum December 31, 2021. The charter commenced on May 31, 2020. The "G. P. Zafirakis" is a 179,492 dwt Capesize dry bulk vessel built in 2014. This employment is anticipated to generate approximately $6.34 million of gross revenue for the minimum scheduled period of the time charter.

09:16 EDT CI Security announces strategic agreement with Synnex - CI Security announced a strategic agreement with Synnex. The agreement enables Synnex to expand its security services line card by adding CI Security's Critical Insight MDR solution, as well as a menu of services such as penetration testing and risk assessments. CI Security's Critical Insight MDR platform adds an outsourced security operations center to Synnex customers' existing infrastructure.

09:15 EDT Comtech receivees $2.8M order from overseas agency - Comtech Telecommunications announced that during its third quarter of fiscal year 2020, its Mission-Critical Technologies group's Space & Component Technology, or SCT, division, which is part of Comtech's Government Solutions segment, received a $2.8 million order from an overseas agency for ground station maintenance and support.

09:12 EDT Ecolab gains EPA approval for laundry disinfectant effective against SARS-CoV-2 - Ecolab's AdvaCare Disinfectant has received the first approval given by the U.S. Environmental Protection Agency, or EPA, for a laundry disinfectant and oxidizer emerging viral pathogen claim as effective against SARS-CoV-2, the virus that causes COVID-19. AdvaCare Disinfectant is an EPA-registered laundry disinfectant and the concentrated formulation is permitted for use in commercial and industrial laundry operations. The current U.S. EPA-approved master label for AdvaCare Disinfectant now contains use directions for emerging viral pathogens, such as SARS-CoV-2 and Clostridium difficile at an attainable daily use level for all textiles laundered in a commercial laundry. The disinfectant is listed on the EPA's LIST N website for products that can be used against SARS-CoV-2.

09:07 EDT VivoPower completes electrial works for 89 MWdc Goonumbla solar project - VivoPower announced that its wholly-owned subsidiary in Australia, J.A. Martin has recently completed all electrical works for the 89 MWdc Goonumbla Solar Farm near the town of Parkes in New South Wales, the city made famous for broadcasting images of the Apollo 11 moon landing. The project was completed in partnership with lead contractor Grupo Gransolar. Energised earlier this month, the Goonumbla project will generate approximately 195,000 MWh of clean energy per year, enough to power 45,000 homes and avoid 140,000 tonnes of carbon dioxide emissions. Electricity produced by the project will be sold under a power purchase agreement with Australian Federal government-owned generator and retailer Snowy Hydro Limited.

09:04 EDT Eros International enters collaboration with Epic Games to use Unreal Engine - Eros International entered into a strategic collaboration with Epic Games related to Eros's use of Epic's Unreal Engine across the production slate. The use of Unreal Engine will help in accelerating production efficiencies using rendering technology, eliminating physical production restrictions on set during shoot and postproduction. Additionally, the strategic human resource investment into the collaboration will result in support for the development of Eros's talent pool.

09:02 EDT CASE Construction Equipment delivers 125 units to Angola's Ministry of Transport - CASE Construction Equipment, has recorded one of its largest deliveries for 2020 with an order for 125 units from the Angolan Ministry of Transport. Amidst the global COVID-19 pandemic, the construction sector has begun to see an uptake in activity as governments of countries with a downward trend in contagion enter into their respective next phases, reinstating select construction activities. This has been reflected within CNH Industrial construction equipment business with recent deliveries to customers in Australia, China, Russia and Southeast Asia. The latest signs of encouragement come from Africa, with this substantial delivery in Angola. The result of a tender won by Redondo y Garcia SA, a key CASE partner in the country, the order consists of a mix of Backhoe Loaders, Crawler Excavators, Dozers and Graders. Aftermarket services tied to this delivery are being supported by local CASE dealer Ivecar SA. Despite the logistical slowdown related to COVID-19, the delivery has been successfully concluded. Throughout the pandemic crisis, CNH Industrial has continued to support its global dealer network and to maintain aftermarket services. The majority of CNH Industrial's 67 global plants have reopened. To ensure the health and safety of its employees, the Company has established a global COVID-19 Safety Protocol throughout its plants and logistics centers, which encompasses 48 different measures and is in compliance with local regulations in all countries in which it operates.

09:01 EDT Virtu sees adj. net trading income $425M-$440M for two months ended May 31 - Virtu Financial announced preliminary estimates of its top line results for second quarter to date through May 31, 2020. Results for the second quarter 2020 are expected to be reported in early August. On a preliminary estimated basis, Virtu expects its results of operations for the two months ended May 31, 2020 to reflect: Trading Income, net between $460M and $474M; Adjusted Net Trading Income between $425M and $440M; Average Daily Adjusted Net Trading Income between $10.37M and $10.73M per day.

08:58 EDT Frontline launches ATM Equity Offering - Frontline announced the Company entered into an Equity Distribution Agreement dated June 3, 2020, with Morgan Stanley & Co. or the offer and sale of up to $100M of common shares of Frontline. In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell its common shares at any time and from time to time through Morgan Stanley as its sales agent. Sales of the common shares, if any, will be made by means of ordinary brokers' transactions on NYSE or otherwise at market prices prevailing at the time of sale, at prices related to the prevailing market prices, or at negotiated prices. The net proceeds of this offering will be used to opportunistically fund growth opportunities and for general corporate purposes.

08:44 EDT Marathon Patent Group announces installation of 700 M30S+ ASIC Miners - Marathon Patent Group announced the completed installation of 700 M30S+ ASIC Bitcoin Miners that were purchased on May 11, 2020. The company is awaiting delivery of 1,160 Bitmain S19 Pro ASIC Miners in the next 60 days. On May 19, 2020, Marathon announced the reduction of the conversion price of Convertible Note originally issued on August 31, 2017. The entire principal balance of $999,105.60 and $215,411.30 of accrued interest has been fully converted by the Note holder to Marathon Common stock, reducing the company's Long-Term Debt to zero. This reduction in Debt results in a substantial improvement in the company's Balance Sheet and increases our Stockholders Equity.

08:42 EDT VectoIQ stockholders approve proposed business combination with Nikola - In a regulatory filing, VectoIQ Acquisition noted that a special meeting held on June 2 in lieu of the 2020 annual meeting of stockholders, the company's stockholders approved the proposed business combination of the company and Nikola Corporation, the amendments to VectoIQ's certificate of incorporation proposal, the election of each director nominee pursuant to the election of directors proposal, the stock incentive plan proposal, the Nasdaq proposal, and the employee stock purchase plan proposal, in each case as defined and described in greater detail in the proxy statement.

08:40 EDT Meritor to partially restore base salaries of salaried employees on June 16 - Effective June 16, the base salaries of the company's salaried employees in the United States and Canada will be partially restored, but remain reduced from original levels as follows: CEO/Board of Directors: 20% reduction from 60% reduction; Other officers: 15% reduction from 50% reduction; Executives: 15% reduction from 25% reduction; All other salaried employees in the United States and Canada: 10% reduction from 20% reduction.

08:35 EDT Genasys announces $4.3M U.S. Navy IDIQ contract - Genasys announced it has been awarded a $4.3M indefinite delivery/indefinite quantity contract from the U.S. Navy for LRAD 1000Xi acoustic hailing devices. With the 3-year award, the Navy also placed an initial $1.2M order for delivery this fiscal year.

08:34 EDT Repay Holdings partners with Inovatec Systems on payment channels - Repay Holdings announced its partnership with Inovatec Systems, a provider of cloud-based lending solutions for financial institutions. As an integrated partner with Inovatec, Repay will enable lenders and finance companies on the Inovatec system to accept debit cards, credit cards, and ACH payments through its digital suite of consumer-facing payment channels, including text-to-pay, interactive voice response phone pay, the Repay mobile app, and online payment portals.

08:32 EDT Exagen announces clinical trial in collaboration with Duke University - Exagen announced a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living with lupus. This prospective study will evaluate biomarkers, including the AVISE panel and Cell-Bound Complement Activation Products, that distinguish between changes in subsets of lupus patients with Type 1 and Type 2 systemic lupus erythematosus activity. The Type 1 and Type 2 SLE model was developed at Duke by Megan E.B. Clowse, MD, David Pisetsky, MD, PhD, Jennifer L. Rogers, MD, and colleagues as a means to incorporate the full spectrum of lupus symptoms into the clinical assessment and advance personalized medicine for lupus patients. The model combines patient- and physician- reported measures to group patients into two main categories. Type 1 manifestations are the classical lupus signs and symptoms due to inflammatory processes, and include butterfly rash, joint inflammation, nephritis or vasculitis. Patients categorized as Type 2 have a general feeling of being unwell and may present with fatigue, depression, anxiety, widespread pain, or difficulty sleeping.

08:31 EDT Agraflora Organics announces evidence package submission to Health Canada - AgraFlora Organics announced that on May 28, 2020, its subsidiary The Edibles and Infusions Corporation submitted its Site Evidence Package to Health Canada for a Standard Processing License for its 51,000-Square-foot fully-automated edibles manufacturing facility in Winnipeg, Manitoba. The recently completed 51,500 square-foot production ready Edibles Facility utilizes state of the art equipment technology and when fully operational, EIC expects to produce over 250,000 pieces of precisely dosed edibles per eight-hour shift. With the facility's equipment efficiencies, EIC can easily pivot to provide specific dosing and custom candies to meet regulatory requirements and customer specifications, while also reducing the risk of contamination or degradation of the cannabis inputs. The company currently holds a Research and Development License from Health Canada which it intends to use to develop and perfect the recipes and formulations for client edibles, increasing customer satisfaction, reducing operational risk and allowing the company to move into revenue quickly once the Standard Processing License is obtained. Although there is no guarantee on licensing timelines, management estimates that first revenue post-licensing will be delivered in Q4 2020.

08:28 EDT Future Farm, High Purity Natural Products to merge - Future Farm Technologies and High Purity Natural Products announced that on May 27, 2020 the parties signed a Letter of Intent to merge. The companies will sign a definitive Merger Agreement and subsequently close in the immediate future. Future Farm has already been providing strategic and financial resources to support the rapid growth of High Purity's business. That business includes both High Purity's established operations as a leader in advanced contract manufacturing of health and wellness products featuring CBD and its recent expansion into the hand sanitizer product lines that retailers and other business customers are demanding in the face of the COVID-19 pandemic. Future Farm's support to date has included $125,000 in working capital loans, introductions to large, creditworthy customers, facilitating key parts of the High Purity hand sanitizer supply chain and identifying and closing new sources of nondilutive growth capital. The merger of the two companies immediately implements a major step in Future Farm's core strategy: becoming a leading supplier of pharma-grade health and wellness products, including those which feature hemp-derived CBD. High Purity is a leading Massachusetts-based advanced white label and contract manufacturer of cutting-edge nutraceutical and cosmetic products using organic and natural plant extracts, including hemp-derived CBD. High Purity has been a leading manufacturer of these products utilizing hemp and pure CBD extracts since the Massachusetts Department of Agriculture started its hemp program in 2018. From its inception, High Purity has diligently expanded its customer base and now sells its high-quality products to a broad array of customers, including leading consumer brands and prominent retailers nationwide. Pursuant to the terms of the Letter of Intent, Future Farm will acquire 100% of the outstanding membership units of High Purity by means of a reverse triangular merger in which a subsidiary of Future Farm will be merged into High Purity. As a result of the Transaction, High Purity will become a wholly owned subsidiary of Future Farm. All outstanding membership units of High Purity would be exchanged for newly issued common shares of Future Farm at the closing of the Transaction. The consideration to be provided by Future Farm to the holders of High Purity's outstanding membership units in the Transaction would be 15 million common shares of Future Farm. The Transaction is not expected to constitute a fundamental change or reverse-takeover for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.

08:24 EDT Boeing, TUI reach agreement to resolve 737 MAX grounding impacts - European travel company TUI and Boeing have agreed on a comprehensive package of measures to offset the consequences of the grounding of the 737 MAX. While the details of the agreement are confidential, it provides compensation which covers a significant portion of the financial impact, as well as credits for future aircraft orders, TUI said in a statement. The compensation will be realized over the next two years. In addition, both parties have agreed to a revised delivery schedule for the 61 737 MAX aircraft on order, meaning that TUI will get fewer 737 MAX deliveries from Boeing than previously planned in the next several years. The associated payment schedules have been adapted accordingly. As a result of this less than half of the originally planned 737 MAX aircraft will be delivered to TUI in the next two years. On average, compared with the original scheduling, the 737 MAX deliveries will be delayed by approximately two years. This will significantly reduce TUI's capital and financing requirements for aircraft in the coming years and supports TUI's plan to reduce the size of fleet of its five European airlines in the wake of the Corona crisis. It was agreed not to disclose the financial details of the agreement. Fritz Joussen, CEO of TUI Group, commented on the agreement with Boeing: "We have reached a fair agreement that strengthens our long-standing relationship with Boeing. The agreement provides TUI with compensation for a large part of costs that were incurred due to the grounding of the 737 MAX. The new delivery schedule gives us considerable flexibility because we will have fewer new aircraft delivered in the next years. This enables TUI to rapidly adapt its fleet growth to the currently challenging market environment. And it supports our plan to downsize the aircraft fleet and reduce the capital requirements for aircraft investments in the Group."

08:22 EDT Histogen says enrollment underway in Phase 1b/2a trial of HST 001 - Histogen announced that it will be featured as a presenting company at BIO Digital 2020, being held virtually June 8-12, 2020. In addition to completion of its merger with Conatus Pharmaceuticals in May 2020, enrollment is currently underway in Histogen's Phase 1b/2a clinical trial of its lead product candidate, HST 001, for male pattern hair loss. Histogen also anticipates clinical advancement of HST 002, a novel dermal filler product, and HST 003, a product targeting joint cartilage regeneration, this year.

08:20 EDT Horizon Therapeutics announces a series of data presentations for Krystexxa - Horizon Therapeutics announced a series of data presentations that demonstrate Krystexxa can be co-prescribed with three commonly used immunomodulators in rheumatology to potentially help more people with chronic gout refractory to conventional therapies achieve complete and durable response to therapy. Presentations during the European League Against Rheumatism, or EULAR, European E-Congress of Rheumatology include new data from the MIRROR open-label trial of Krystexxa with methotrexate, as well as in-practice cases and an investigator-initiated trial for two other immunomodulators with Krystexxa, all of which show high response rates. An analysis of real-world use of Krystexxa with immunomodulators will also be discussed in an oral presentation on June 4. While Krystexxa has been traditionally used as a biologic monotherapy with a clinically demonstrated impact on uncontrolled gout, recent literature suggests that using an immunomodulator such as methotrexate has the potential to increase the durability of response to Krystexxa. New data from the MIRROR open-label trial showed that when treated with oral methotrexate prior to and throughout the Krystexxa treatment period, 78.6% of patients achieved a complete response, defined as the proportion of serum uric acid, or sUA, responders during Month 6. All patients tolerated methotrexate and no new safety concerns were identified. Additional data presented during the EULAR E-Congress 2020 indicate the benefit of this enhanced therapeutic approach may extend to other commonly used immunomodulators, helping to prevent the development of anti-drug antibodies with biologics: Methotrexate addition to Krystexxa allowed most patients to complete therapy and achieve a full therapeutic response. Based on experience in a community rheumatology practice between 2017 and 2019, this chart review included 10 patients treated with a combination of Krystexxa and methotrexate. Most were treated with subcutaneous methotrexate. All 10 patients experienced a rapid decrease in serum uric acid and 80% were complete responders. Two patients discontinued treatment before infusion 12; one due to a mild infusion reaction and one lost to follow-up. A gout flare was reported in one patient and no new safety concerns were identified. Leflunomide as an immunomodulator showed high response rates with Krystexxa. This in-practice case series shows 70% achieved a complete response when co-treated with Krystexxaand leflunomide. Three patients discontinued or were lost to follow-up. The findings indicated that low-to-moderate immunomodulation could minimize or prevent the formation of anti-drug antibodies and increase the number of patients who gain the full benefit of a course of treatment, with no new safety concerns. Azathioprine with Krystexxa could increase the frequency of patients experiencing long-term lowering of serum urate. The interim data for this investigator-initiated open-label trial of 12 uncontrolled gout patients showed that at the time of data publication 60% achieved a complete response; two patients were still receiving treatment with persistent urate-lowering. No adverse events related to azathioprine were reported and gout flares were noted in six patients.

08:18 EDT Global Blood Therapeutics announces new employment inducement grants - Global Blood Therapeutics announced that on June 1, 2020, the compensation committee of GBT's board of directors granted seven new employees restricted stock units for an aggregate of 34,000 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The 2017 Inducement Equity Plan was adopted by GBT's board of directors in January 2017 and has been amended and restated from time to time.

08:17 EDT Boeing jumps after Third Point reveals stake in monthly report - Dan Loeb's Third Point Offshore Fund listed Boeing (BA) as one of its monthly winners for May, along with Disney (DIS), Burlington Stores (BURL), Charter Communications (CHTR) and TE Connectivity (TEL). In its latest quarterly filing representing its holdings as of March 31, Third Point did not disclose a stake in Boeing. With Loeb's hedge fund seemingly taking a new stake in the plane maker, shares of Boeing are up 2% to $156.80 in premarket trading.

08:15 EDT Allakos initiates patient recruitment for AK002 registrational studies - Allakos announced that it is recruiting patients for two previously announced registrational clinical studies of AK002; a Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and a Phase 2/3 study in eosinophilic esophagitis. Top-line safety and efficacy results from both studies are expected in the second half of 2021. The Phase 3 EG and/or EoD study and the Phase 2/3 EoE study follow positive results from ENIGMA, the Company's multicenter, randomized, double-blind, placebo-controlled Phase 2 study in patients with EG and/or EoD. Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis Study Design: The multicenter, randomized, double-blind, placebo-controlled Phase 3 study will enroll approximately 160 patients with active, biopsy-confirmed EG and/or EoD. Patients will be randomized 1:1 to receive: 1.0 mg/kg of antolimab for the first month followed by five doses of 3.0 mg/kg given monthly, or monthly placebo. The co-primary endpoints of the study are: the proportion of patients achieving less than or equal to 4 eosinophils in 5 hpfs in the stomach and/or less than or equal to15 eosinophils in 3 hpfs in the duodenum and absolute change in Total Symptom Score measured using the daily patient reported symptom questionnaire used in ENIGMA. The TSS-6 comprises the six most frequent and severe symptoms reported in ENIGMA. The multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study will enroll approximately 300 patients with active, biopsy-confirmed EoE. Patients will be randomized 1:1:1 to receive: six antolimab doses of 1.0 mg/kg given monthly, 1.0 mg/kg of antolimab for the first month followed by five doses of 3.0 mg/kg given monthly, or monthly placebo. The co-primary endpoints of the study are: the proportion of patients achieving less than or equal to6 eosinophils in a single hpf and absolute change in dysphagia symptoms measured using a daily patient reported symptom questionnaire known as the Dysphagia Symptom Questionnaire.

08:14 EDT American Eagle reports Q1 total ending inventory at cost down $34M to $422M - American Eagle reported in its Q1 earnings release, "Total ending inventory at cost decreased $34 million or 8% to $422 million. The company continues to clear through AE spring and summer merchandise to position both brands for new back-to-school collections in late July. Inventory optimization initiatives currently being implemented will streamline assortments, provide greater alignment of inventory to sales plans and better utilize supply chain strengths to chase product demand."

08:12 EDT BeyondSpring gets DSMB recommendation to continue NSCLC Phase 3 Dublin-3 study - BeyondSpring announced that the Company has reached the second interim analysis for its Phase 3 Dublin-3 in the treatment of non-small cell lung cancer with lead asset, Plinabulin. Upon reviewing the safety and efficacy data of over 500 patients and approximately 300 pre-specified death events, the Data & Safety Monitoring Board has advised BeyondSpring to continue the study without any modifications. Study 103 evaluates the anti-cancer effects of Plinabulin in combination with docetaxel, compared to docetaxel alone, in second- / third-line Epidermal Growth Factor Receptor wild-type NSCLC patients, with a primary endpoint of overall survival. EGFR wild-type NSCLC patients make up 85 percent of the NSCLC population; second- / third- line NSCLC with EGFR wild-type represents one of the most significant clinical challenges with limited treatment options. Currently approved I/O therapies and the chemotherapy pemetrexed have advanced to first-line treatment, leaving a therapeutic void for patients whose cancer progresses. The remaining approved two chemotherapy options, docetaxel and the docetaxel-ramucirumab combination, have significant limitations. These limitations force second- / third-line patients to choose between minimal gains in OS over docetaxel alone with extremely high severe neutropenia rates at over 40 percent with both options. The onslaught of COVID-19 is causing oncologists to reconsider the impact of neutropenia on cancer care. Recent studies indicate that the death rate for NSCLC patients afflicted with COVID-19 are as high as 55 percent1 in the New York healthcare system, making the avoidance of neutropenia, as well as OS extension, the key priorities in cancer care. In a Phase 2 clinical trial, the Plinabulin-docetaxel combination demonstrated the efficacy benefit of a long duration of response and a median OS benefit of 4.6 months over docetaxel, the standard of care, alone. Most importantly, in that study, adding Plinabulin to docetaxel reduced the frequency of patients who experienced Grade 4 neutropenia from 33.8 percent to less than 5 percent. Thus, the Plinabulin-docetaxel combination potentially improves on anti-cancer efficacy, while reducing toxicity, compared with docetaxel alone.

08:11 EDT Taseko Mines reports operational performance at Gibraltar and Florence Copper - Taseko Mines reported "strong" operating results at both its Gibraltar Copper Mine and Florence Copper Project. There have been no operational disruptions or known cases of COVID-19 at any of Taseko's locations to-date. The Gibraltar mine is currently operating to the new plan and through the first five months of the year has produced approximately 57 million pounds of copper and nearly 900,000 pounds of molybdenum. Production guidance for 2020 remains unchanged at 130 million pounds +/-5% with the expectation of being at the higher end of the range. At its Florence Copper Project, the test facility continues to operate on a steady-state basis with no disruption to operation. PLS grade in the center recovery well has been roughly 2g per liter since November and recently the SX/EW plant producing at a rate of approximately 1M pounds of copper cathode per year. Discussions regarding a joint venture with interested parties and other potential lenders regarding project financing are ongoing.

08:08 EDT Iqvia, Quest Diagnostics JV collaborates with Thermo Fisher to use NGS platform - Q2 Solutions, a clinical trial laboratory services organization resulting from an Iqvia (IQV) and Quest Diagnostics (DGX) joint venture, or JV, announced its partnership with Thermo Fisher Scientific (TMO) to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing, or NGS, platform, to deliver clinical trial lab results economically with speed.

08:06 EDT Universal Technical reopens hands-on training labs at 10 of 13 campuses - Universal Technical has reopened hands-on training labs at ten of its thirteen campuses. Labs at three remaining campuses are scheduled to open by June 15. Modified in alignment with Centers for Disease Control and Prevention and local health department guidelines, the labs allow students participating in online courses to continue the in-person portion of their education and train for good, stable jobs essential to the nation's infrastructure.

08:05 EDT Great Panther Silver restarts Mexican operations - Great Panther reports the restart of mining operations in Mexico following a government order adding mining to the list of essential services. The restart is following a phased approach to accommodate new protocols in response to COVID-19. The company's operating and health plans for both mines, in alignment with most recent government regulations, received approval from the Mexican Institute of Social Security. Mining and processing operations have commenced at the Topia Mine in Durango, and processing at the Guanajuato Mine Complex in Guanajuato is expected to start next week. The company's Tucano Gold Mine in Brazil continues to operate under strict protocols to limit the spread of COVID-19. The company does not anticipate any interruption of operations caused by lack of tailings storage capacity at Topia in 2020.

08:05 EDT Vera Bradley leveraging elements of CARES Act to enhance financial health - Beginning in mid-March, the Company began taking several actions to navigate the COVID-19 crisis, protect its financial position, maximize liquidity, and to position the Company for a strong reopening and future. Those actions included: Temporarily closing all of its Vera Bradley store locations on March 19. Temporarily furloughing approximately 80% of its workforce mid-quarter. Temporarily reducing base compensation for remaining salaried Associates, with reductions on a graduated scale ranging from 15% to 30%, and 75% for the Chief Executive Officer. Temporarily suspending cash compensation to the board of directors. Temporarily suspending its share buyback program. Drawing $60 million from its previously unused $75 million revolving credit agreement. Temporarily eliminating the Company 401(k) and Associate charitable donation matches. Tightly managing inventory levels through the cancellation of orders, delay of receipts, or seeking price concessions where possible. Actively working with landlords on addressing rent abatement, payment terms, accelerating store closures, and delaying or cancelling certain planned new store openings. Reducing non-payroll operating expenses, including but not limited to, marketing and travel. Extending vendor payment terms. In addition, the Company is leveraging elements of the Coronavirus Aid Relief and Economic Security Act to enhance the financial well-being of Associates and to maximize the financial health of the Company.

08:02 EDT Criteo reports May revenue "better than expected" - Criteo provided an interim update on its Q2 financial performance as of May 29. In its Q2 guidance, the company had assumed a continued decline of revenues through the month of May due to COVID-19. As of May 29, however, a continued decline of the company's revenues for the month of May compared to April had not materialized as anticipated. Therefore, as of May 29, overall revenue trends have been better than expected at the time of guidance. Additionally, as of May 29, the company believes it is on track to achieve its cost savings targets as anticipated.

07:49 EDT Honda reports May U.S. sales down 16.9% to 120,977 vehicles - Last night, American Honda reported sales declined 16.9% from the prior year in May to 120,977 vehicles, including sales of 110,636 Honda brand vehicles and 10,341 Acura brand vehicles.

07:38 EDT Warner Music, Blavatnik Family Foundation announce $100M fund to support causes - Warner Music Group, its directors and management, and the Blavatnik Family Foundation announced a $100M fund to support charitable causes related to the music industry, social justice and campaigns against violence and racism. An advisory panel made up of appointees from Warner Music Group and the Blavatnik Family Foundation will establish procedures to identify and support those in the music community, and organizations strengthening education, and promoting equality, opportunity, diversity and inclusion. The advisory panel will determine the amount of the financial gifts and timing.

07:34 EDT A.H. Belo declares quarterly cash dividend of 4c per share - A. H. Belo Corporation announced that the Company's Board of Directors declared a quarterly cash dividend of $0.04 per share on June 2, 2020. The dividend will be payable on September 4, 2020 to shareholders of record at the close of business on August 14, 2020.

07:30 EDT Secoo Holding trading resumes

07:27 EDT AMC Entertainment: 'Substantial doubt' on ability to continue as going concern - The company said, "The COVID-19 pandemic has had and will continue to have a significant and adverse impact on our business. As a result of the pandemic, all of our theatres worldwide have temporarily suspended operations through late June, and we are generating no revenue from admissions, food and beverage sales, or other revenue, which represent substantially all of our revenue and cash flow from operations. The ultimate duration of the pandemic and of responsive governmental regulations, including shelter-in-place orders and mandated business closures, is uncertain and we may need to extend such suspension with respect to some or all of our theatres. We cannot predict when or if our business will return to normal levels. If the coronavirus continues to spread in the parts of the world where we operate, we may elect on a voluntary basis to again halt operations (after their reopening) certain of our theatres, or governmental officials may order additional closures, impose further restrictions on travel or introduce social distancing measures such as limiting the number of people allowed in a theatre at any given time. While we plan to eliminate variable costs and reduce fixed costs to the extent possible, we continue to incur significant cash outflows, including interest payments, taxes, critical maintenance capital expenditures, and certain compensation and benefits payments. We cannot be certain that we will have access to sufficient liquidity to meet our obligations for the time required to allow our cash generating operations to resume or normalize. We may not be able to obtain additional liquidity and any relief provided by lenders, governmental agencies, and business partners may not be adequate and may include onerous terms. Due to these factors, substantial doubt exists about our ability to continue as a going concern for a reasonable period of time. We may face difficulty in maintaining relationships with our landlords, vendors, motion picture distributors, customers, and employees during the suspension period. We are unable to predict the availability of supplies or workforce necessary to operate when we re-open. Since the outbreak of the COVID-19 virus, movie studios have suspended production of movies and delayed the release date of movies. Some movie studios have also reduced or eliminated the theatrical exclusive release window as theatres are not operating. The longer and more severe the pandemic, including repeat or cyclical outbreaks beyond the one we are currently experiencing, the more severe the adverse effects will be on our business, results of operations, liquidity, cash flows, financial condition, access to credit markets and ability to service our existing and future indebtedness. Even when the COVID-19 pandemic subsides, we cannot guarantee that we will recover as rapidly as other industries, or that we will recover as rapidly as others within the industry due to our strong footprint in densely populated areas. For example, once applicable government restrictions are lifted, it is unclear how quickly theatres will be permitted to resume operations and how quickly patrons will return to our theatres once theatres resume operations, which may be a function of continued concerns over safety and social distancing and/or depressed consumer sentiment due to adverse economic conditions, including job losses, among other things. Even once theatres resume operations, a single case of COVID-19 in a theatre could result in additional costs and further closures, or a "second wave" or recurrence of COVID-19 cases could cause another widespread suspension of operations. If we do not respond appropriately to the pandemic, or if customers do not perceive our response to be adequate, we could suffer damage to our reputation, which could significantly adversely affect our business. Furthermore, the effects of the pandemic on our business could be long-lasting and could continue to have adverse effects on our business, results of operations, liquidity, cash flows and financial condition, some of which may be significant, and may adversely impact our ability to operate our business after our temporary suspension ends on the same terms as we conducted business prior to the pandemic."

07:25 EDT Replimune Group expects inital data from Phase 1 trial of RP2 by end of 2020 - The ongoing Phase 1 clinical trial evaluating the safety, tolerability, and optimal dose for further development of RP2 alone and in combination with Opdivo remains on track, with initial safety and efficacy data from the single agent RP2 part of the clinical trial together with initial data in combination with Opdivo expected to be presented by the end of 2020.

07:23 EDT Replimune says enrollment ongoing in study of RP1 in combination with Libtayo - Enrollment in the 240-patient registration-directed Phase 2, randomized, controlled clinical trial is ongoing and is expected to take approximately 18 to 24 months with enrollment intended in the US, Australia, Canada, and European countries including the United Kingdom.

07:22 EDT Campbell Soup: Some changes will be more episodic, some will be lasting

07:20 EDT Campbell Soup sees supply challenges, moving quickly to add targeted capacity

07:18 EDT BeiGene announces approval of BRUKINSA in China - BeiGene announced that its BTK inhibitor BRUKINSA has received approval from the China National Medical Products Administration in two indications - the treatment of adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who have received at least one prior therapy, and the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. Both new drug applications were previously granted priority review by the Center for Drug Evaluation of the NMPA. BRUKINSA received accelerated approval from the U.S. Food and Drug Administration as a treatment for MCL in adult patients who have received at least one prior therapy in November 2019. The NMPA approval of BRUKINSA in patients with R/R CLL/SLL is based on results from a single-arm pivotal Phase 2 trial conducted in 91 patients in China. Clinical efficacy data in the BRUKINSA label in China, as assessed by independent review committee per iwCLL 2008 criteria for CLL and Lugano Classification 2014 for SLL, include an overall response rate of 62.6%, including a complete response rate of 3.3%, a partial response rate of 59.3%, and the PR with lymphocytosis rate was 22% The most common adverse reactions reported in the label in China were neutropenia, thrombocytopenia, hematuria, purpura, anemia, leukopenia, pneumonia, upper respiratory tract infection, hemorrhage, and rash. The incidence of Grade greater than or equal to3 adverse reactions was 69.2%. The incidence of serious adverse reactions was 19.8%, and the most common serious adverse reaction was pneumonia. The NMPA approval of BRUKINSA in patients with R/R MCL is based on results from a single-arm pivotal Phase 2 trial conducted in 86 patients in China. Clinical efficacy data in the BRUKINSA label in China, as assessed by IRC per Lugano Classification 2014, include the ORR of 83.7%, including a CR rate of 68.6% and a partial response PR rate of 15.1%. The most common adverse reactions reported in the label in China were neutropenia, rash, leukopenia, thrombocytopenia, and anemia. The incidence of serious adverse reactions was 15.1%, and common serious adverse reactions included pneumonia, hemorrhage, and thrombocytopenia.

07:15 EDT Calibre Mining announces maiden Mineral Resource estimate at Panteon deposit - Calibre Mining announced a maiden Mineral Resource estimate for the Panteon deposit at its Limon mine. Panteon is a high-grade vein located approximately 150 metres from the currently-producing Santa Pancha underground mine. Roscoe Postle Associates estimates that the Panteon deposit currently contains an Indicated Mineral Resource of 90,000 tonnes at an average grade of 9.88 g/t Au for 29,000 contained ounces, with an additional Inferred Mineral Resource of 303,000 tonnes at an average grade of 6.79 g/t Au for 66,000 contained ounces. The Panteon deposit is hosted within a low sulfidation Bonanza style epithermal vein system typical of the Limon district. From 1965 to 1992, high grade gold mineralization was mined along a 1,000 metre long section of the vein system to vertical depths ranging from 100 to 350 metres below surface. This maiden resource estimate incorporates a total of 122 diamond drill holes, including 12 holes drilled by Calibre in late 2019 and the first quarter of 2020. Calibre's initial drilling focused on a 75 by 150 metre section of vein thickening near the southern intersection of the Panteon vein with the Santa Pancha vein system to the east. Drilling to date has tested this section over a vertical range of 115 to 175 metres depth from surface. The mineral resource currently measures approximately 730 metres along strike, ranges from two to eight metres wide with a vertical extent of 260 metres. The Panteon mineral resource extends to a vertical depth of approximately 230 metres from surface. The deepest hole intersected 3.25 g/t gold over 2.0 metres at a down-hole depth of 422.3 to 424.3 metres, approximately 45 metres below the limit of this maiden resource and highlights the potential that the deposit may be open at depth. The Panteon mineral resource estimate has an effective date of May 15, 2020 and was constrained within a 2.00 g/t Au grade shell using a $1,500 per ounce gold price assumption. The Panteon mineral resource is not included in Calibre's 2019 Annual Information Form consolidated mineral resource and reserves table. Historical access to the Panteon deposit was provided by a shaft which currently provides ventilation for the Santa Pancha underground mine. Anticipating positive results from the drilling campaign, in the first quarter of 2020 the Company commenced development towards Panteon from existing Santa Pancha infrastructure, completing 125 metres of horizontal development and putting the Company in an excellent position to develop the required mine infrastructure. Mine planning is currently under way to mine ore from Panteon in the fourth quarter of 2020. The current Limon exploration program will resume as drills re-mobilize in June to focus on resource expansion opportunities at Panteon, the main Limon vein system and other prospective targets in the broader Limon district. Since the start of commercial production in 1941, the Limon district has produced in excess of 3.5 million ounces of gold.

07:12 EDT Altair announces significant software updates - Altair announced the most significant software update release in the company's history. All of Altair's software products have been updated with advancements in user experience and countless new features, including intuitive workflows that empower users to streamline product development, allowing customers to get to market faster. The software update release expands on the number of solutions available for designers, engineers, data analysts, IT and HPC professionals, facility managers, and more to drive better decisions and accelerate the pace of innovation. It broadens the scope of the new user experience, enables access to more physics, data analytics, and machine learning, and makes the Altair software delivery method more flexible and accessible.

07:09 EDT Pluristem partners with CRISPR-IL National Consortium for genome-editing - Pluristem Therapeutics announced that it was selected as a member of the CRISPR-IL consortium, a group funded by the Israeli Innovation Authority. Pluristem's Vice President Research & Intellectual Property, Racheli Ofir, will lead CRISPR-IL's pharma working group. CRISPR-IL is funded by the Israeli Innovation Authority with a total budget of NIS36M, or approximately $10M, for a period of 18 months, with a potential for extension of an additional 18 months and additional budget from the Israeli Innovation Authority. CRISPR-IL participants include leading companies, and medical and academic institutions. In addition to Pluristem, key participants from industry include BTG - Bio-technology General Israel, Colors Farm, Hazera Seeds, NRgene, Evogene, TargetGene Biotechnologies and Rahan Meristem Ltd.; medical institutions include Sheba Medical Center and Schneider Children's Medical Center; and members from academia include Bar-Ilan University, Ben Gurion University of the Negev, Hebrew University of Jerusalem, the Weizmann Institute of Science, IDC Herzliya, and Tel-Aviv University. CRISPR is a genome-editing technology for detecting and modifying DNA sequences. It is used as a tool to enable genetic changes. The technology enables the development of unique bio-based products and novel therapeutics while reducing the time and cost of development. Current CRISPR-based workflows target precise areas within the DNA; however, these workflows still face several challenges, which prevent more extensive use of this tool, including: accidental off-target modification, inefficient modifications and inaccurate measuring tools to ascertain if the modification was effective as intended. The CRISPR-IL consortium intends to develop an AI-based system to provide users improved genome-editing workflows. The system aims to provide end-to-end solutions, from the user interface to an accurate measurement tool. The system is expected to include the computational design of on-target DNA modification, with minimal accidental, off-target modifications, improve modification efficiency and provide an accurate measuring tool to ensure the desired modification was made.

07:08 EDT GSX Techedu refutes 'false allegations' in Grizzly Research's follow up report - GSX Techedu said, "GSX Techedu refuted the false allegations in Grizzly Research's follow up report, dated June 2. After thoroughly analyzing the report, the company believes it contains numerous errors, unsubstantiated statements and groundless speculations. Specifically, the report alleged that Gaotu's student enrollment numbers are inflated based on data it obtained from API. However, most of the Spring semester courses have been removed from Gaotu's website after Gaotu completed the majority of its Spring semester students' recruitment. Moreover, the Company enhanced its data security capabilities, so that the data that Grizzly obtained, including student enrollments and course numbers, are encrypted and don't reflect actual operational data. Furthermore, the report wrongly alleged GSX's marketing activities as illegal. The company strictly complies with all relevant legal and regulatory requirements, as well as the terms and conditions of social media platforms. The Company reserves the right to take legal actions against the photoshopped images from Grizzly. GSX remains committed to maintaining the highest standards of corporate governance, as well as transparent and timely disclosure in compliance with the applicable rules and regulations of the SEC and the NYSE. The company remains focused on further developing its business, better serving its students, and creating value for shareholders over the long term."

07:07 EDT Intrepid Potash returns to compliance under NYSE listing standards - Intrepid Potash announced that on June 2, 2020 it received written notice from the New York Stock Exchange stating that Intrepid had regained compliance with the applicable NYSE minimum share price requirement. On April 17, 2020, Intrepid previously received notice from the NYSE that its stock price had fallen out of compliance with NYSE continued listing standards. Under NYSE listing standards, Intrepid could regain compliance at any time during the original 6 month cure period if its common stock had a closing price of at least $1.00 per share on the last trading day of any calendar month during the cure period and an average closing price of at least $1.00 per share of common stock over the 30-trading-day period ending on the last trading day of that month. Since the original notice from the NYSE, Intrepid's stock price improved and closed on Friday, May 29, 2020 at $1.23 per share, with an average closing price exceeding $1.00 per share over the previous 30 trading days. Accordingly, Intrepid has regained compliance with the NYSE minimum share price requirement and the matter is now closed.

07:05 EDT Qudian, Seeco Holding announce investment, strategic partnership - Qudian (QD) and Secoo Holding (SECO) announced that Qudian and Secoo have entered into a definitive agreement, pursuant to which Qudian has agreed to purchase a total of up to 10,204,082 newly issued Class A ordinary shares of Secoo for an aggregate purchase price of up to $100,000,003.60, reflecting a per share purchase price of $9.80. Following the completion of all transactions contemplated under the definitive agreement, Qudian will hold approximately 28.9% of Secoo's issued and outstanding shares, becoming its largest shareholder. In addition, Qudian and Secoo will also enter into a business cooperation agreement, which will set forth the key areas for the two companies' strategic cooperation in the online luxury e-commerce business space.

07:02 EDT Novavax, AGC Biologics to partner to produce NVX-CoV2373 component - AGC Biologics has announced that it will partner with Novavax on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M, the adjuvant component of the vaccine, in order to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax' proprietary nanoparticle technology. AGC Biologics will optimize process development for scaled-up production of Matrix-M to significantly increase Novavax' capacity to deliver doses in 2020 and 2021.

07:00 EDT Eli Lilly to present new data for Olumiant at EULAR - Eli Lilly will present new data for Olumiant at the virtual European Congress of Rheumatology, or EULAR. Highlights from Olumiant data being presented at the virtual meeting include new long-term data in patients living with rheumatoid arthritis, or RA, as well as data from an investigational trial in patients with systemic lupus erythematosus, or SLE. At this year's meeting, Lilly will share results from a long-term study that evaluated the efficacy of Olumiant in patients with moderate to severe RA during three years of treatment. The study measured the achievement of clinically-relevant outcomes, including low disease activity, or LDA, as measured by the simplified disease activity index, or SDAI, in DMARD-naive patients and patients with an inadequate response to methotrexate, or MTX-IR, from treatment initiation to three years. Patients in this study were treated with Olumiant 4-mg once daily, an approved dose outside of North America. The study found that among patients with an inadequate response to MTX, 52% of patients initially treated with Olumiant were in a state of SDAI LDA at week 24 and this rate was maintained through week 148. Lilly will also share an updated integrated safety analysis of Olumiant in the treatment of RA using data from 3,770 patients who were treated with the medicine for up to 8.4 years. The study found that Olumiant's safety profile remains consistent with what has been previously reported, with no increase in the rates of safety topics of interest, including serious infections, herpes zoster, major adverse cardiovascular events, deep-vein thrombosis and/or pulmonary embolism, non-melanoma skin cancer and non-NMSC malignancies. No new safety signals were identified.

06:59 EDT Atlantic Power says Calstock PPA extended to Dec. 16, Oxnard PPA expired - Atlantic Power provides the following update on the Power Purchase Agreements, or PPAs, for its Calstock and Oxnard plants: "Calstock is an approximately 35 megawatt biomass plant located in Hearst, Ontario. The PPA with the Ontario Electricity Financial Corporation, which had been scheduled to expire in June, was recently extended to December 16, on existing terms. The extension provides the provincial government additional time to evaluate the future role of the Calstock plant and biomass generation in the province. The Company expects Project Adjusted EBITDA from Calstock in the July through December period will be lower than the comparable period in 2019 primarily due to an expected increase in fuel costs, as a result of lower production from the local mills due to the coronavirus pandemic. Oxnard is an approximately 49 megawatt gas-fired plant located in Oxnard, California. The PPA with Southern California Edison expired on May 25, 2020 and was not renewed or extended. The Company recently executed a Reliability Must Run, or RMR, agreement with the California Independent System Operator that became effective June 1 and will expire December 31. The RMR is conditioned upon the approval of the Federal Energy Regulatory Commission, or FERC; the application for approval was submitted to the FERC on May 28 and is pending. The Company expects that Project Adjusted EBITDA from Oxnard under the RMR agreement will be de minimis. Although the Company had not assumed continued operation of either Calstock or Oxnard beyond the second quarter, the short-term contract extension for Calstock and the RMR agreement for Oxnard do not result in a change to 2020 Project Adjusted EBITDA guidance of $175 million to $190 million."

06:57 EDT Secoo Holding trading halted, news pending

06:55 EDT Haemonetics announces blood filter supply agreement, sale of Fajardo operations - Haemonetics announced that it has entered into a definitive agreement to sell its Fajardo, Puerto Rico, manufacturing operations to GVS, S.p.A. Haemonetics said in a release, "Under the terms of the agreement, upon closing, Haemonetics will retain all intellectual property rights to its proprietary blood filters currently manufactured at its Fajardo facility, while GVS will obtain certain operating assets, including manufacturing equipment and inventory and a sublease to the facility. In connection with the proposed transaction, Haemonetics and GVS will also enter into a long-term supply and development agreement that will, among other things, grant GVS exclusive rights to manufacture and supply the blood filters currently produced at the Fajardo facility for Haemonetics. As part of this transaction, Haemonetics employees who work in the Fajardo facility will become GVS employees. This transaction is expected to close in the second quarter of calendar 2020."

06:48 EDT Retailwinds trading halted, news pending

06:35 EDT Nice's Digital Evidence Management Solution adopted by four U.K. police forces - Nice announced that a consortium of four UK police forces - Hampshire Constabulary, Thames Valley Police, Surrey Police and Sussex Police -, operating as the South East Regional Integrated Policing Programme, has signed a contract with Nice to deploy the Nice Investigate Digital Evidence Management Solution. SERIP will roll out Nice Investigate to more than 12,000 officers to streamline investigations. Running on the Microsoft Azure cloud, Nice Investigate is a one-stop solution for automating manual processes around the collection, management, analysis and sharing of all types of digital evidence.

06:19 EDT Cinemark reports Q1 adjusted EBITDA $66.2M vs. $152.25M a year ago

06:09 EDT OpGen expands partnership with NY State Department of Health and IDC - OpGen's strategic collaboration with the New York State Department of Health to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is entering into its second year expansion phase. OpGen will continue to work together with DOH's Wadsworth Center, participating healthcare systems, and collaborators such as Infectious Disease Connect, which recently combined with ILundefinedM Health Solutions, to expand the reach of the platform, increase the volume of testing, and enhance data collection. The second-year expansion phase will focus on integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. The second year contract includes a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450K to OpGen.

06:06 EDT Facebook software engineer resigns over Zuckerberg's policy on Trump posts - A Facebook employee has resigned in protest of Mark Zuckerberg's decision to allow controversial posts from President Trump to remain on the site. In a post on LinkedIn, software engineer Timothy Aveni said he is on the lookout for a new job thanks to "Facebook's continued refusal to act on the president's bigoted messages aimed at radicalizing the American public. He added "I'm scared for my country, and I'm watching my company do nothing to challenge the increasingly dangerous status quo." Aveni criticized Facebook for "moving the goalposts every time Trump escalates, finding excuse after excuse to not act on increasingly dangerous rhetoric." Reference Link

06:03 EDT Axonics' wireless patient remote control approved by FDA - Axonics announced FDA approval of its new wireless patient Remote Control with SmartMRI technology for the Axonics r-SNM System under a premarket approval supplement. The new Remote Control simplifies the process by which patients can receive a full-body MRI. The new patient Remote Control with SmartMRI technology will be included in all new orders of the Axonics r-SNM System in the U.S. beginning this month. The Axonics r-SNM System is approved for 1.5T full-body MRI scans in the United States and both 1.5T and 3.0T full-body MRI scans in Canada and Europe.

06:01 EDT Patterson-UTI reports an average of 80 drilling rigs operating in May - Patterson-UTI reported that for the month of May, the company had an average of 80 drilling rigs operating. For the two months ended May 31, the company had an average of 92 drilling rigs operating.

05:38 EDT FSD Pharma receives FDA approval to aubmit IND using FSD-201 on COVID patients - FSD Pharma announced that the FDA has given the company permission to submit an Investigational New Drug Application, or IND, for the use of FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus. FSD said in a release, "Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. Based on the FDA feedback received to date, we expect the trial will be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg or 1200mg twice-daily plus standard of care, or SOC, versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19. Eligible patients will present with symptoms consistent with influenza/coronavirus signs (fever, dry cough, malaise, difficulty breathing) and/or newly documented positive COVID-19 disease. The primary endpoint is to determine if FSD-201 plus SOC provides a significant improvement in clinical status (i.e., shorter time to symptom relief). Key secondary objectives include determining if FSD-201 plus SOC demonstrates additional benefit in terms of safety, objective assessments such as length of time to normalization of fever, length of time to improvement of oxygen saturation and length of time to clinical progression including time to mechanical ventilation or hospitalization, and length of hospital stay. The exploratory endpoint is cytokine clearance as measured by Enzyme Linked Immunosorbent Assay, or ELISA. The treatment period is expected to be 14 days. All patients who experience clinical benefit are expected to continue to receive their assigned treatment until study completion."